Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CAD | P27708 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186701 | 0.86 | ITGB3 (0.40) | ITGB3ITGA2BCADCYP1A2ALOX15 | |
| SCHEMBL185633 | 0.84 | GAA (0.40) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL186846 | 0.81 | CAD (0.35) | ITGB3ITGA2BBLMCADCYP1A2 | |
| SCHEMBL186665 | 0.81 | CAD (0.46) | CAD | |
| SCHEMBL16401433 | 0.78 | HSD17B10 (0.37) | HSD17B10ALDH1A1POLBBLM | |
| SCHEMBL186077 | 0.77 | NPSR1 (0.40) | ITGB3ITGA2BCADCYP1A2ALOX15 | |
| SCHEMBL185955 | 0.76 | ITGB3 (0.41) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL186542 | 0.75 | ITGB3 (0.36) | ITGB3ITGA2BALDH1A1CYP2C19 | |
| SCHEMBL10186994 | 0.74 | ALDH1A1 (0.42) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL186628 | 0.73 | HDAC8 (0.49) | ITGB3ITGA2BALDH1A1POLBCAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2004352-B1 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2004352-B1 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7964181-B2 | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964181-B2 | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964181-B2 | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| CN-101484171-A | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES INC (US) | 2009-07-15 | — | — | CN | disclosed |
| US-20090069224-A1 | Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069224-A1 | Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-2004352-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007115164-A9 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007115164-A9 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007115164-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115164-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | ARGLU1, QRFPR, ARG1 | ITGB3 3374/4885ITGA2B 2688/4885HSD17B10 3859/4885 |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | ARGLU1, ARG1, QRFPR | ITGB3 3628/4885ITGA2B 2641/4885HSD17B10 2679/4885 |
| US-20090069224-A1 | Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics | MC1R, MC3R, MC5R | ITGB3 4141/4885ITGA2B 4370/4885HSD17B10 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.